Search

Your search keyword '"Kazanowska, B."' showing total 232 results
Start Over Author "Kazanowska, B."
232 results on '"Kazanowska, B."'

1. IMPACT OF RITUXIMAB ON IMMUNE STATUS FOLLOWING THERAPY IN CHILDREN AND ADOLESCENTS WITH HIGH-RISK MATURE B-CELL NON-HODGKIN LYMPHOMA: RESULTS OF THE INTER-B-NHL RITUX 2010 TRIAL

Author

Alexander, S., primary, Aupérin, A., additional, Bomken, S., additional, Csoka, M., additional, Kazanowska, B., additional, Chiang, A., additional, Moreno, M. Andrés, additional, Uyttebroeck, A., additional, Burke, A., additional, Zsiros, J., additional, Pillon, M., additional, Bollard, C., additional, Barkauskas, D., additional, Wheatley, K., additional, Patte, C., additional, Gross, T., additional, and Minard-Colin, V., additional

Published
2022
Full Text
View/download PDF

3. IDENTIFICATION OF GENETIC PREDISPOSITION TO CHILDHOOD LYMPHOMAS – PRELIMINARY DATA

Author

Szmyd, B., primary, Krajewska, K., additional, Trelińska, J., additional, Miarka-Walczyk, K., additional, Urbańska, Z., additional, Wypyszczak, K., additional, Walenciak, J., additional, Wziątek, A., additional, Irga-Jaworska, N., additional, Radwańska, M., additional, Dudkiewicz, E., additional, Krawczuk-Rybak, M., additional, Dembowska-Bagińska, B., additional, Kazanowska, B., additional, Matysiak, M., additional, Młynarski, W., additional, and Pastorczak, A., additional

Published
2022
Full Text
View/download PDF

4. INTER-B NHL-RITUX-2010 TRIAL FOR CHILDREN/ADOLESCENTS WITH HIGH-RISK MATURE B-NHL: SAFETY AND EFFICACY IN PATIENTS TREATED WITH RITUXIMAB AND LMB CHEMOTHERAPY

Author

Minard-Colin, V., primary, Aupérin, A., additional, Burke, A., additional, Alexander, S., additional, Moreno, M., additional, Buffardi, S., additional, Uyttebroeck, A., additional, Bollard, C., additional, Zsiros, J., additional, Csoka, M., additional, Kazanowska, B., additional, Chiang, A., additional, Verschuur, A., additional, Miles, R., additional, Wotherspoon, A., additional, Barkauskas, D., additional, Wheatley, K., additional, Vassal, G., additional, Adamson, P., additional, Gross, T., additional, Patte, C., additional, and Pillon, M., additional

Published
2022
Full Text
View/download PDF

5. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (cns) tumors and tropomyosin receptor kinase (trk) fusion.

Author

Lamoureux A.-A., Fisher M., Lemelle L., Pfaff E., Kramm C., De Wilde B., Kazanowska B., Hutter C., Pfister S.M., Sturm D., Jones D., Orbach D., Pierron G., Raskin S., Drilon A., Diamond E., Harada G., Zapotocky M., Ellezam B., Weil A.G., Venne D., Barritault M., Leblond P., Coltin H., Hammad R., Tabori U., Hawkins C., Hansford J.R., Meyran D., Erker C., McFadden K., Sato M., Gottardo N.G., Dholaria H., Noroxe D.S., Goto H., Ziegler D.S., Lin F.Y., Parsons D.W., Lindsay H., Wong T.-T., Liu Y.-L., Wu K.-S., Franson A.F., Hwang E., Aguilar-Bonilla A., Cheng S., Cacciotti C., Massimino M., Schiavello E., Wood P., Hoffman L.M., Cappellano A., Lassaletta A., Van Damme A., Llort A., Gerber N.U., Ceruso M.S., Bendel A.E., Skrypek M., Hamideh D., Mushtaq N., Walter A., Jabado N., Alsahlawi A., Farmer J.-P., Abadi C.C., Mueller S., Mazewski C., Aguilera D., Robison N., O'Halloran K., Abbou S., Berlanga P., Geoerger B., Ora I., Moertel C.L., Razis E.D., Vernadou A., Doz F., Laetsch T.W., Perreault S., Lamoureux A.-A., Fisher M., Lemelle L., Pfaff E., Kramm C., De Wilde B., Kazanowska B., Hutter C., Pfister S.M., Sturm D., Jones D., Orbach D., Pierron G., Raskin S., Drilon A., Diamond E., Harada G., Zapotocky M., Ellezam B., Weil A.G., Venne D., Barritault M., Leblond P., Coltin H., Hammad R., Tabori U., Hawkins C., Hansford J.R., Meyran D., Erker C., McFadden K., Sato M., Gottardo N.G., Dholaria H., Noroxe D.S., Goto H., Ziegler D.S., Lin F.Y., Parsons D.W., Lindsay H., Wong T.-T., Liu Y.-L., Wu K.-S., Franson A.F., Hwang E., Aguilar-Bonilla A., Cheng S., Cacciotti C., Massimino M., Schiavello E., Wood P., Hoffman L.M., Cappellano A., Lassaletta A., Van Damme A., Llort A., Gerber N.U., Ceruso M.S., Bendel A.E., Skrypek M., Hamideh D., Mushtaq N., Walter A., Jabado N., Alsahlawi A., Farmer J.-P., Abadi C.C., Mueller S., Mazewski C., Aguilera D., Robison N., O'Halloran K., Abbou S., Berlanga P., Geoerger B., Ora I., Moertel C.L., Razis E.D., Vernadou A., Doz F., Laetsch T.W., and Perreault S.

Abstract

BACKGROUND: TRK fusions are detected in less than 3% of CNS tumors. Given their rarity, there are limited data on the clinical course of these patients. METHOD(S): We contacted 166 oncology centers worldwide to retrieve data on patients with TRK fusion-driven CNS tumors. Data extracted included demographics, histopathology, NTRK gene fusion, treatment modalities and outcomes. Patients less than 18 years of age at diagnosis were included in this analysis. RESULT(S): Seventy-three pediatric patients with TRK fusion-driven primary CNS tumors were identified. Median age at diagnosis was 2.4 years (range 0.0-17.8) and 60.2 % were male. NTRK2 gene fusions were found in 37 patients (50.7%), NTRK1 and NTRK3 aberrations were detected in 19 (26.0%) and 17 (23.3%), respectively. Tumor types included 38 high-grade gliomas (HGG; 52.1%), 20 low-grade gliomas (LGG; 27.4%), 4 embryonal tumors (5.5%) and 11 others (15.1%). Median follow-up was 46.5 months (range 3-226). During the course of their disease, a total of 62 (84.9%) patients underwent surgery with a treatment intent, 50 (68.5%) patients received chemotherapy, 35 (47.9%) patients received radiation therapy, while 34 (46.6%) patients received NTRK inhibitors (3 as first line treatment). Twenty-four (32.9%) had no progression including 9 LGG (45%) and 9 HGG (23.6%). At last follow-up, only one (5.6%-18 evaluable) patient with LGG died compared to 11 with HGG (35.5%-31 evaluable). For LGG the median progression-free survival (PFS) after the first line of treatment was 17 months (95% CI: 0.0-35.5) and median overall survival (OS) was not reached. For patients with HGG the median PFS was 30 months (95% CI: 11.9-48.1) and median OS was 182 months (95% CI 20.2-343.8). CONCLUSION(S): We report the largest cohort of pediatric patients with TRK fusion-driven primary CNS tumors. These results will help us to better understand clinical evolution and compare outcomes with ongoing clinical trials.

Published
2022

6. HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.

Author

Lamoureux, A-A, Fisher, M, Lemelle, L, Pfaff, E, Kramm, C, De Wilde, B, Kazanowska, B, Hutter, C, Pfister, SM, Sturm, D, Jones, D, Orbach, D, Pierron, G, Raskin, S, Drilon, A, Diamond, E, Harada, G, Zapotocky, M, Ellezam, B, Weil, AG, Venne, D, Barritault, M, Leblond, P, Coltin, H, Hammad, R, Tabori, U, Hawkins, C, Hansford, JR, Meyran, D, Erker, C, McFadden, K, Sato, M, Gottardo, NG, Dholaria, H, Nørøxe, DS, Goto, H, Ziegler, DS, Lin, FY, Parsons, DW, Lindsay, H, Wong, T-T, Liu, Y-L, Wu, K-S, Franson, AF, Hwang, E, Aguilar-Bonilla, A, Cheng, S, Cacciotti, C, Massimino, M, Schiavello, E, Wood, P, Hoffman, LM, Cappellano, A, Lassaletta, A, Van Damme, A, Llort, A, Gerber, NU, Ceruso, MS, Bendel, AE, Skrypek, M, Hamideh, D, Mushtaq, N, Walter, A, Jabado, N, Alsahlawi, A, Farmer, J-P, Abadi, CC, Mueller, S, Mazewski, C, Aguilera, D, Robison, N, O’Halloran, K, Abbou, S, Berlanga, P, Geoerger, B, Øra, I, Moertel, CL, Razis, ED, Vernadou, A, Doz, F, Laetsch, TW, Perreault, S, Lamoureux, A-A, Fisher, M, Lemelle, L, Pfaff, E, Kramm, C, De Wilde, B, Kazanowska, B, Hutter, C, Pfister, SM, Sturm, D, Jones, D, Orbach, D, Pierron, G, Raskin, S, Drilon, A, Diamond, E, Harada, G, Zapotocky, M, Ellezam, B, Weil, AG, Venne, D, Barritault, M, Leblond, P, Coltin, H, Hammad, R, Tabori, U, Hawkins, C, Hansford, JR, Meyran, D, Erker, C, McFadden, K, Sato, M, Gottardo, NG, Dholaria, H, Nørøxe, DS, Goto, H, Ziegler, DS, Lin, FY, Parsons, DW, Lindsay, H, Wong, T-T, Liu, Y-L, Wu, K-S, Franson, AF, Hwang, E, Aguilar-Bonilla, A, Cheng, S, Cacciotti, C, Massimino, M, Schiavello, E, Wood, P, Hoffman, LM, Cappellano, A, Lassaletta, A, Van Damme, A, Llort, A, Gerber, NU, Ceruso, MS, Bendel, AE, Skrypek, M, Hamideh, D, Mushtaq, N, Walter, A, Jabado, N, Alsahlawi, A, Farmer, J-P, Abadi, CC, Mueller, S, Mazewski, C, Aguilera, D, Robison, N, O’Halloran, K, Abbou, S, Berlanga, P, Geoerger, B, Øra, I, Moertel, CL, Razis, ED, Vernadou, A, Doz, F, Laetsch, TW, and Perreault, S

Abstract

BACKGROUND: TRK fusions are detected in less than 3% of CNS tumors. Given their rarity, there are limited data on the clinical course of these patients. METHODS: We contacted 166 oncology centers worldwide to retrieve data on patients with TRK fusion-driven CNS tumors. Data extracted included demographics, histopathology, NTRK gene fusion, treatment modalities and outcomes. Patients less than 18 years of age at diagnosis were included in this analysis. RESULTS: Seventy-three pediatric patients with TRK fusion-driven primary CNS tumors were identified. Median age at diagnosis was 2.4 years (range 0.0–17.8) and 60.2 % were male. NTRK2 gene fusions were found in 37 patients (50.7%), NTRK1 and NTRK3 aberrations were detected in 19 (26.0%) and 17 (23.3%), respectively. Tumor types included 38 high-grade gliomas (HGG; 52.1%), 20 low-grade gliomas (LGG; 27.4%), 4 embryonal tumors (5.5%) and 11 others (15.1%). Median follow-up was 46.5 months (range 3-226). During the course of their disease, a total of 62 (84.9%) patients underwent surgery with a treatment intent, 50 (68.5%) patients received chemotherapy, 35 (47.9%) patients received radiation therapy, while 34 (46.6%) patients received NTRK inhibitors (3 as first line treatment). Twenty-four (32.9%) had no progression including 9 LGG (45%) and 9 HGG (23.6%). At last follow-up, only one (5.6%-18 evaluable) patient with LGG died compared to 11 with HGG (35.5%-31 evaluable). For LGG the median progression-free survival (PFS) after the first line of treatment was 17 months (95% CI: 0.0-35.5) and median overall survival (OS) was not reached. For patients with HGG the median PFS was 30 months (95% CI: 11.9-48.1) and median OS was 182 months (95% CI 20.2-343.8). CONCLUSIONS: We report the largest cohort of pediatric patients with TRK fusion-driven primary CNS tumors. These results will help us to better understand clinical evolution and compare outcomes with ongoing clinical trials.

Published
2022

8. The Results of Treatment of Acute Lymphoblastic Leukemia Relapses in the Polish Children’s Leukemia/Lymphoma Study Group

Author

Bogusławska-Jaworska, J., Pisarek, J., Chybicka, A., Kazanowska, B., Armata, J., Balwierz, W., Bubała, H., Jackowska, T., Michalewska, D., Ochocka, M., Radwanska, U., Milewska, R. Rokicka, Rytlewska, M., Skomra, S., Sladkowska, G., Wachowiak, J., Wieczorek, M., Zelenay, E., Sońta-Jakimczuk, D., Woźniak, A., Neth, Rolf, editor, Frolova, Elena, editor, Gallo, Robert C., editor, Greaves, Melvyn F., editor, Afanasiev, Boris V., editor, and Elstner, Elena, editor

Published
1992
Full Text
View/download PDF

9. Adenovirus infection among pediatric patients with cancer and in pediatric recipients of hematopoietic stem cell: A multicenter nationwide study

Author

Zając‐Spychała, O., primary, Pieczonka, A., additional, Wachowiak, J., additional, Frączkiewicz, J., additional, Salamonowicz, M., additional, Kałwak, K., additional, Gorczyńska, E., additional, Kazanowska, B., additional, Wróbel, G., additional, Chybicka, A., additional, Czyżewski, K., additional, Dziedzic, M., additional, Wysocki, M., additional, Zalas‐Więcek, P., additional, Szmydki‐Baran, A., additional, Hutnik, Ł., additional, Matysiak, M., additional, Irga‐Jaworska, N., additional, Bień, E., additional, Drożyńska, E., additional, Stolpa, W., additional, Sobol‐Milejska, G., additional, Pierlejewski, F., additional, Młynarski, W., additional, Gryniewicz–Kwiatkowska, O., additional, Gietka, A., additional, Dembowska‐Bagińska, B., additional, Semczuk, K., additional, Dzierżanowska‐Fangrat, K., additional, Gamrot‐Pyka, Z., additional, Woszczyk, M., additional, Urbanek‐Dądela, A., additional, Karolczyk, G., additional, Płonowski, M., additional, Krawczuk‐Rybak, M., additional, Zaucha‐Prażmo, A., additional, Kowalczyk, J., additional, Goździk, J., additional, and Styczyński, J., additional

Published
2020
Full Text
View/download PDF

15. Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children

Author

Minard-Colin V, Auperin A, Pillon M, Burke G, Barkauskas D, Wheatley K, Delgado R, Alexander S, Uyttebroeck A, Bollard C, Zsiros J, Csoka M, Kazanowska B, Chiang A, Miles R, Wotherspoon A, Adamson P, Vassal G, Patte C, Gross T, and European Intergrp Childhood Non-Ho

Subjects
hemic and lymphatic diseases
Abstract

BACKGROUND Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited. METHODS We conducted an open-label, international, randomized, phase 3 trial involving patients younger than 18 years of age with high-risk, mature B-cell non-Hodgkin's lymphoma (stage III with an elevated lactate dehydrogenase level or stage IV) or acute leukemia to compare the addition of six doses of rituximab to standard lymphomes malins B (LMB) chemotherapy with standard LMB chemotherapy alone. The primary end point was event-free survival. Overall survival and toxic effects were also assessed. RESULTS Analyses were based on 328 patients who underwent randomization (164 patients per group); 85.7% of the patients had Burkitt's lymphoma. The median follow-up was 39.9 months. Events were observed in 10 patients in the rituximab-chemotherapy group and in 28 in the chemotherapy group. Event-free survival at 3 years was 93.9% (95% confidence interval [CI], 89.1 to 96.7) in the rituximab-chemotherapy group and 82.3% (95% CI, 75.7 to 87.5) in the chemotherapy group (hazard ratio for primary refractory disease or first occurrence of progression, relapse after response, death from any cause, or second cancer, 0.32; 95% CI, 0.15 to 0.66; one-sided P=0.00096, which reached the significance level required for this analysis). Eight patients in the rituximab-chemotherapy group died (4 deaths were disease-related, 3 were treatment-related, and 1 was from a second cancer), as did 20 in the chemotherapy group (17 deaths were disease-related, and 3 were treatment-related) (hazard ratio, 0.36; 95% CI, 0.16 to 0.82). The incidence of acute adverse events of grade 4 or higher after prephase treatment was 33.3% in the rituximab-chemotherapy group and 24.2% in the chemotherapy group (P=0.07); events were related mainly to febrile neutropenia and infection. Approximately twice as many patients in the rituximab-chemotherapy group as in the chemotherapy group had a low IgG level 1 year after trial inclusion. CONCLUSIONS Rituximab added to standard LMB chemotherapy markedly prolonged event-free survival and overall survival among children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin's lymphoma and was associated with a higher incidence of hypogammaglobulinemia and, potentially, more episodes of infection.

Published
2020

18. 061 - INTER-B NHL-RITUX-2010 TRIAL FOR CHILDREN/ADOLESCENTS WITH HIGH-RISK MATURE B-NHL: SAFETY AND EFFICACY IN PATIENTS TREATED WITH RITUXIMAB AND LMB CHEMOTHERAPY

Author

Minard-Colin, V., Aupérin, A., Burke, A., Alexander, S., Moreno, M., Buffardi, S., Uyttebroeck, A., Bollard, C., Zsiros, J., Csoka, M., Kazanowska, B., Chiang, A., Verschuur, A., Miles, R., Wotherspoon, A., Barkauskas, D., Wheatley, K., Vassal, G., Adamson, P., Gross, T., Patte, C., and Pillon, M.

Published
2022
Full Text
View/download PDF

22. The Results of Treatment of Acute Lymphoblastic Leukemia Relapses in the Polish Children’s Leukemia/Lymphoma Study Group

Author

Bogusławska-Jaworska, J., primary, Pisarek, J., additional, Chybicka, A., additional, Kazanowska, B., additional, Armata, J., additional, Balwierz, W., additional, Bubała, H., additional, Jackowska, T., additional, Michalewska, D., additional, Ochocka, M., additional, Radwanska, U., additional, Milewska, R. Rokicka, additional, Rytlewska, M., additional, Skomra, S., additional, Sladkowska, G., additional, Wachowiak, J., additional, Wieczorek, M., additional, Zelenay, E., additional, Sońta-Jakimczuk, D., additional, and Woźniak, A., additional

Published
1992
Full Text
View/download PDF

23. Survival in children, adolescents and young adults with metastatic synovial sarcoma : A Report of the Cooperative Weichteilsarkom Studiengruppe (CWS)

Author

Scheer, M., Roessig, C., Pekrun, A., Vokuhl, C., Leuschner, I., Veit, I., Sparber-Sauer, M., Kazanowska, B., Niggli, F., Ladenstein, R., Ljungman, Gustaf, Muenter, M., von Kalle, T., Bielack, S., Klingebiel, T., Koscielniak, E., Scheer, M., Roessig, C., Pekrun, A., Vokuhl, C., Leuschner, I., Veit, I., Sparber-Sauer, M., Kazanowska, B., Niggli, F., Ladenstein, R., Ljungman, Gustaf, Muenter, M., von Kalle, T., Bielack, S., Klingebiel, T., and Koscielniak, E.

Published
2018

24. Results of Treatment in Children with B-Cell Lymphoma: Report on the Polish Leukemia/Lymphoma Study Group

Author

Bogusławska-Jaworska, J., Kazanowska, B., Rodziewicz-Magott, B., Pietras, W., Armata, J., Daszkiewicz, P., Dłużniewska, A., Koehler, M., Matysiak, M., Ochocka, M., Radwańska, U., Rokicka-Milewska, R., Sońta-Jakimczyk, D., Zmudzka, I., Neth, Rolf, editor, Gallo, Robert C., editor, Greaves, Melvyn F., editor, Gaedicke, Gerhard, editor, Gohla, Sven, editor, Mannweiler, Klaus, editor, and Ritter, Jörg, editor

Published
1989
Full Text
View/download PDF

25. Progress in Treatment of Advanced Non-Hodgkin’s Lymphoma in Children — Report on Behalf of the Polish Children’s Leukemia/Lymphoma Study Group

Author

Bogusławska-Jaworska, J., Rodziewicz, B., Kazanowska, B., Armata, J., Cyklis, R., Daszkiewicz, P., Dłużniewska, A., Matysiak, M., Ochocka, M., Radwańska, U., Rokicka-Milewska, R., Sroczyńska, M., Wójcik, Z., Żmudzka, I., Heimpel, H., editor, Huhn, D., editor, Mueller-Eckhardt, C., editor, Ruhenstroth-Bauer, G., editor, Neth, Rolf, editor, Gallo, Robert C., editor, Greaves, Melvyn F., editor, and Kabisch, Hartmut, editor

Published
1987
Full Text
View/download PDF

26. Progress in Treatment of Children with non-Hodgkin Lymphoma: A Report of the Polish Leukemia and Lymphoma Study Group

Author

Bogusławska-Jaworska, J., Rodziewicz, B., Kazanowska, B., Armata, J., Cyklis, R., Daszkiewicz, P., Dłużniewska, A., Matusiak, M., Ochocka, M., Radwańska, U., Rokicka-Milewska, R., Sońta-Jakimczyk, D., Sroczyńska, M., Wójcik, Z., Żmudzka, I., Heimpel, H., editor, Huhn, D., editor, Mueller-Eckhardt, C., editor, Ruhenstroth-Bauer, G., editor, Büchner, T., editor, Schellong, G., editor, Hiddemann, W., editor, Urbanitz, D., editor, and Ritter, J., editor

Published
1987
Full Text
View/download PDF

28. Prognosis of Children with Localized Rhabdomyosarcoma (RMS) of Genitourinary Regions (GU) Treated in 5 Prospective Studies of the Cooperative Weichsteilsarkom Studiengruppe (CWS)

Author

Koscielniak, E., Fuchs, J., Seitz, G., Leuschner, I., Scheer, M., Sparber-Sauer, M., Kazanowska, B., Ladenstein, R., Ljungman, Gustaf, Niggli, F., Bielack, S., Muenter, M., von Kalle, T., Hallmen, E., Klingebiel, T., Koscielniak, E., Fuchs, J., Seitz, G., Leuschner, I., Scheer, M., Sparber-Sauer, M., Kazanowska, B., Ladenstein, R., Ljungman, Gustaf, Niggli, F., Bielack, S., Muenter, M., von Kalle, T., Hallmen, E., and Klingebiel, T.

Published
2016

30. Better Outcome With Maintenance Therapy : Pediatric Patients With Stage Iv Soft Tissue Sarcoma Benefit From Long Term Therapy Compared To Sct Or No Further Therapy

Author

Bochennek, K., Dantonello, T., Borkhardt, A., Dirksen, U., Eggert, A., Greiner, J., Handgretinger, R., Kazanowska, B., Kratz, C., Ladenstein, R., Ljungman, Gustaf, Hallmen, E., Koscielniak, E., Klingebiel, T., Bochennek, K., Dantonello, T., Borkhardt, A., Dirksen, U., Eggert, A., Greiner, J., Handgretinger, R., Kazanowska, B., Kratz, C., Ladenstein, R., Ljungman, Gustaf, Hallmen, E., Koscielniak, E., and Klingebiel, T.

Published
2015

31. Powierzchniowa ekspresja receptora TSLPR (CRLF2) maskuje predykcyjny wpływ delecji genu IKZF1 na poziom minimalnej choroby resztkowej w trakcie indukcji remisji dziecięcej ostrej białaczki limfoblastycznej (ALL)

Author

Pastorczak, A., primary, Sędek, Ł., additional, Braun, M., additional, Madzio, J., additional, Sonsala, A., additional, Fendler, W., additional, Chmielewska, M., additional, Taha, J., additional, Górniak, P., additional, Romiszewska, M., additional, Matysiak, M., additional, Derwich, K., additional, Lejman, M., additional, Kowalczyk, J., additional, Badowska, W., additional, Niedźwiedzki, M., additional, Kazanowska, B., additional, Szczepański, T., additional, and Młynarski, W., additional

Published
2015
Full Text
View/download PDF

32. Ekspresja genu GATA-3 zależy od wariantu polimorfizmu rs3824662 i jest związana z przebiegiem klinicznym ostrej białaczki limfoblastycznej z prekursorów linii B (BCP-ALL)

Author

Madzio, J., primary, Pastorczak, A., additional, Braun, M., additional, Tomasik, B., additional, Romiszewska, M., additional, Matysiak, M., additional, Derwich, K., additional, Lejman, M., additional, Jerzy, K., additional, Badowska, W., additional, Kazanowska, B., additional, Szczepański, T., additional, Styczyński, J., additional, Trelińska, J., additional, Zalewska-Szewczyk, B., additional, Irga-Jaworska, N., additional, Fendler, W., additional, and Młynarski, W., additional

Published
2015
Full Text
View/download PDF

33. Wartość prognostyczna inaktywacji genów CDKN2A i CDKN2B w komórkach ostrej białaczki limfoblastycznej

Author

Braun, M., primary, Pastorczak, A., additional, Fendler, W., additional, Madzio, J., additional, Taha, J., additional, Ramiszewska, M., additional, Matysiak, M., additional, Derwich, K., additional, Lejman, M., additional, Kowalczyk, J., additional, Badowska, W., additional, Kazanowska, B., additional, Szczepański, T., additional, Styczyński, J., additional, Trelińska, J., additional, Zalewska-Szewczyk, B., additional, Irga-Jaworska, N., additional, and Młynarski, W., additional

Published
2015
Full Text
View/download PDF

34. Analiza związku zmienności w genie NBN z przebiegiem klinicznym dziecięcej ostrej białaczki limfoblastycznej (ALL)

Author

Tomasik, B., primary, Pastorczak, A., additional, Madzio, J., additional, Taha, J., additional, Braun, M., additional, Romiszewska, M., additional, Matysiak, M., additional, Derwich, K., additional, Lejman, M., additional, Kowalczyk, J., additional, Badowska, W., additional, Kazanowska, B., additional, Szczepański, T., additional, Styczyński, J., additional, Trelińska, J., additional, Zalewska-Szewczyk, B., additional, Fendler, W., additional, Irga-Jaworska, N., additional, and Młynarski, W., additional

Published
2015
Full Text
View/download PDF

35. Progress in Treatment of Children with non-Hodgkin Lymphoma: A Report of the Polish Leukemia and Lymphoma Study Group

Author

Bogusławska-Jaworska, J., primary, Rodziewicz, B., additional, Kazanowska, B., additional, Armata, J., additional, Cyklis, R., additional, Daszkiewicz, P., additional, Dłużniewska, A., additional, Matusiak, M., additional, Ochocka, M., additional, Radwańska, U., additional, Rokicka-Milewska, R., additional, Sońta-Jakimczyk, D., additional, Sroczyńska, M., additional, Wójcik, Z., additional, and Żmudzka, I., additional

Published
1987
Full Text
View/download PDF

36. Prognosis of Children and Adolescents with Soft Tissue Ewing Tumors (STET) Treated in 3 Consecutive, Prospective Studies of the Cooperative Weichsteilsarkom Studiengruppe (CWS)

Author

Koscielniak, E., Dantonello, T., Blank, B., Seitz, G., Leuschner, I., Kazanowska, B., Ladenstein, R., Ljungman, Gustaf, Niggli, F., Bielack, S., Hallmen, E., Klingebiel, T., Koscielniak, E., Dantonello, T., Blank, B., Seitz, G., Leuschner, I., Kazanowska, B., Ladenstein, R., Ljungman, Gustaf, Niggli, F., Bielack, S., Hallmen, E., and Klingebiel, T.

Published
2014

37. Treatment of relapsed rhabdomyosarcoma - Experience of the CWS Study Group

Author

Koscielniak, E., Dantonello, T., Kazanowska, B., Ladenstein, R., Ljungman, Gustaf, Niggli, F., Leuschner, I., Schuck, A., Klingebiel, T., Koscielniak, E., Dantonello, T., Kazanowska, B., Ladenstein, R., Ljungman, Gustaf, Niggli, F., Leuschner, I., Schuck, A., and Klingebiel, T.

Published
2013

42. Remaining Problems and Controversies in the Management of Childhood Head and Neck Soft Tissue Sarcomas: Retrospective (National) Multicenter Study of the Polish Pediatric Solid Tumors Group

Author

Kazanowska, B., primary, Reich, A., additional, Reich, M., additional, Balcerska, A., additional, Balwierz, W., additional, Bodalski, J., additional, Dłużniewska, A., additional, Drożyńska, E., additional, Ka¸tski, K., additional, Kijowski, J., additional, Kowalczyk, J., additional, Kurylak, A., additional, Matysiak, M., additional, Mikołajewska, A., additional, Peregut-Pogorzelski, J., additional, Sopyło, B., additional, Stencel, D., additional, Szewczyk, B., additional, Wachowiak, J., additional, Wieczorek, M., additional, Wysocki, M., additional, and Chybicka, A., additional

Published
2004
Full Text
View/download PDF

47. Infantile haemangiopericytoma - A tumour with high chemosensitivity and favourable prognosis. The Report of the Polish paediatric rare tumours Study,Haemangiopericytoma typu niemowlecego - Guz o wysokiej chemiowrażliwości i korzystnym rokowaniu. Raport Ogólnopolskiego Programu Guzów Rzadkich u Dzieci

Author

Bień, E., Teresa Stachowicz-Stencel, Balcerska, A., Godziński, J., Izycka-Świeszewska, E., Kazanowska, B., Reich, A., Rapała, M., Sulka, W., Perek-Polnik, M., Madziara, W., Mańkowski, P., Nurzyńska-Flak, J., Rybczyńska, A., Bohosiewicz, J., Chybicka, A., Jankowski, A., Kowalczyk, J., Perek, D., Wachowiak, J., and Peregud-Pogorzelski, J.

Catalog

Books, media, physical & digital resources
See catalog results